23.10.2015 MeVis Medical Solutions AG  DE000A0LBFE4

DGAP-News: MeVis Medical Solutions AG: Domination and profit and loss transfer agreement registered with the Commercial Register


 
DGAP-News: MeVis Medical Solutions AG / Key word(s): Miscellaneous MeVis Medical Solutions AG: Domination and profit and loss transfer agreement registered with the Commercial Register 23.10.2015 / 17:30 --------------------------------------------------------------------- Bremen, November 23, 2015 - The MeVis Medical Solutions AG announces today that the domination and profit and loss transfer agreement concluded on August 10, 2015 between the VMS Deutschland Holdings GmbH as the controlling company and MeVis Medical Solutions AG as the controlled company has been registered with the Commercial Register of the Bremen Local Court on October 20, 2015 and has thus become legally effective. The registration in the Commercial Register has been published by the Bremen Local Court on October 21, 2015. The shareholders of the MeVis Medical Solutions AG already approved the domination and profit and loss transfer agreement with a large majority in the extraordinary general meeting on September 29, 2015. Under the domination and profit and loss transfer agreement and upon request of each outside shareholder the VMS Deutschland Holdings GmbH is obliged to acquire MeVis shares against a cash settlement payment in the amount of EUR 19.77 per MeVis share. Optionally, the VMS Deutschland Holdings GmbH guarantees the outside shareholders of MeVis Medical Solutions AG, who chose not to accept the settlement payment offer, for the duration of the domination and profit and loss transfer agreement an annual compensation payment for each MeVis Medical Solutions AG fiscal year and each registered share in MeVis Medical Solutions AG, representing a pro rata amount of the share capital of EUR 1.00 per share, in the amount of EUR 1.13 gross / EUR 0.95 net. --------------------------------------------------------------------- 23.10.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: MeVis Medical Solutions AG Caroline-Herschel-Str. 1 28359 Bremen Germany Phone: +49 421 224 95 0 Fax: +49 421 224 95 999 E-mail: [email protected] Internet: http://www.mevis.de ISIN: DE000A0LBFE4 WKN: A0LBFE Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of News DGAP News Service --------------------------------------------------------------------- 405179 23.10.2015


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 18,54 16,76 18,07 17,13 16,21 18,76 17,34
EBITDA1,2 9,18 7,60 8,25 5,97 4,77 7,99 3,99
EBITDA-Marge3 49,51 45,35 45,66 34,85 29,43 42,59
EBIT1,4 7,96 6,69 8,00 5,81 4,64 7,90 3,89
EBIT-Marge5 42,93 39,92 44,27 33,92 28,62 42,11 22,43
Jahresüberschuss1 5,62 7,17 8,07 5,70 4,55 7,79 4,92
Netto-Marge6 30,31 42,78 44,66 33,27 28,07 41,52 28,37
Cashflow1,7 7,32 5,52 6,55 2,89 9,13 4,86 5,85
Ergebnis je Aktie8 3,09 3,94 4,43 3,13 2,50 4,28 2,70
Dividende8 0,95 0,95 0,95 0,95 0,95 0,95 0,95
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
MeVis Med. Solutions
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0LBFE 25,000 Halten 45,50
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
10,42 10,26 1,02 7,62
KBV KCV KUV EV/EBITDA
2,55 7,77 2,62 10,61
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,95 0,95 3,80 19.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 27.05.2024 - 29.01.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
0,32% -8,48% -0,79% -30,17%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MeVis Medical Solutions AG  ISIN: DE000A0LBFE4 können Sie bei EQS abrufen


Medtech , A0LBFE , M3V , XETR:M3V